Journal
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
Volume 1876, Issue 1, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.bbcan.2021.188557
Keywords
Pancreatic cancer; Monoclonal antibody; Targeted therapy; Oncology
Categories
Funding
- Medical Research Council, U.K. [1962339]
- MRC [1962339] Funding Source: UKRI
Ask authors/readers for more resources
Although antibody therapy for pancreatic cancer has not yet achieved significant success, lessons learned from current research indicate potential future directions for overcoming observed hurdles to achieve clinically efficacious results.
Pancreatic cancer remains an extremely deadly disease, with little improvement seen in treatment or outcomes over the last 40 years. Targeted monoclonal antibody therapy is one area that has been explored in attempts to tackle this disease. This review examines antibodies that have undergone clinical evaluation in pancreatic cancer. These antibodies target a wide variety of molecules, including tumour cell surface, stromal, immune and embryonic pathway targets. We discuss the therapeutic utility of these therapies both as monotherapeutics and in combination with other treatments such as chemotherapy. While antibody therapy for pancreatic cancer has yet to yield significant success, lessons learned from research thus far highlights future directions that may help overcome observed hurdles to yield clinically efficacious results.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available